Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AVROBIO, Inc.
AVROBIO, Inc. News
Jun 20, 2024 - investorplace.com
Why Is Avrobio (AVRO) Stock Moving Today?
Jun 3, 2024 - businesswire.com
Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
May 9, 2024 - businesswire.com
AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
Feb 14, 2024 - businesswire.com
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
AVROBIO, Inc. Quantitative Score
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
AVROBIO, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
AVROBIO, Inc. Financials
Table Compare
Compare AVRO metrics with: | |||
|---|---|---|---|
Earnings & Growth | AVRO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AVRO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AVRO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AVRO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AVROBIO, Inc. Income
AVROBIO, Inc. Balance Sheet
AVROBIO, Inc. Cash Flow
AVROBIO, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Sell |
| Return on Assets | Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Buy |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
AVROBIO, Inc. Executives
| Name | Role |
|---|---|
| Mr. Erik John Ostrowski M.B.A. | President, Interim Chief Executive Officer, Chief Financial Officer & Treasurer |
| Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer |
| Dr. Azadeh Golipour Ph.D. | Chief Technology Officer |
| Mr. Steven N. Avruch J.D. | Chief Legal Officer & Secretary |
| Mr. Jeffrey Medin Ph.D. | Scientific Founder |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Erik John Ostrowski M.B.A. | President, Interim Chief Executive Officer, Chief Financial Officer & Treasurer | Male | 1972 | 1.25M |
| Dr. Essra Ridha FFPM, M.D. | Chief Medical Officer | 1983 | 1.12M | |
| Dr. Azadeh Golipour Ph.D. | Chief Technology Officer | 1980 | 1.01M | |
| Mr. Steven N. Avruch J.D. | Chief Legal Officer & Secretary | Male | 1962 | 506.68K |
| Mr. Jeffrey Medin Ph.D. | Scientific Founder | Male | -- |
AVROBIO, Inc. Insider Trades
| Date | 13 May |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 253700 |
| Date | 13 May |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 216053 |
| Date | 14 May |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 296882 |
| Date | 13 May |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 13 May |
| Name | Leonard Braden Michael |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 13 May | Leonard Braden Michael | 10 percent owner | Acquired | P-Purchase | 253700 |
| 13 May | Leonard Braden Michael | 10 percent owner | Acquired | P-Purchase | 216053 |
| 14 May | Leonard Braden Michael | 10 percent owner | Acquired | P-Purchase | 296882 |
| 13 May | Leonard Braden Michael | 10 percent owner | Disposed | 0 | |
| 13 May | Leonard Braden Michael | 10 percent owner | Disposed | 0 |